| Description: |
Background. The management of patients with multifactorial autoimmune diseases (inflammatory bowel diseases (IBD) and chronic dermatoses) is currently impossible without taking into account the clinical and biological phenotypes of the disease. To develop optimal disease control, it is necessary to study the factors that influence the manifestation, course, and relapse of the diseases. In addition, it is required to understand the phenotypic clinical and immunological parameters of inflammation, which depend on the underlying pathological process, the therapy, and the condition of other organs and systems involved in the underlying pathological process, including the upper respiratory tract. The aim of the study was to determine the main phenotypic clinical and immunological parameters of inflammation in pediatric patients with immune-inflammatory diseases associated with upper respiratory tract pathology (using psoriasis and IBD as an example). Methods. The study included 60 children: 20 patients with psoriasis and 20 children IBD, as well as 20 patients in the control group (conditionally healthy children) aged 6 years to 17 years 11 months. All patients in the study groups were consulted by a pediatrician, an otolaryngologist, an audiologist, and an allergist (if indicated). Patients with psoriasis were examined by a dermatologist, and children with IBD were examined by a gastroenterologist. Instrumental examination methods included nasal and nasopharyngeal endoscopy, otoscopy, tympanometry, and tonal threshold audiometry. Laboratory methods of research: clinical blood test, determination of antistreptolysin O, IL-1α, IL-1β, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, IL-17, IL-18, IL-19, IL-20, IL-23, and TNF-α levels in blood serum; determination of serum proteins (MDC/CCL22) and TLSP/kallikrein in blood serum. All patients in the target groups underwent rapid fecal testing for Helicobacter pylori and microbiological studies (mycological examination of oropharyngeal discharge for Candida albicans fungi; ... |
| Relation: |
https://www.pedpharma.ru/jour/article/view/2696/1743; Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53(3):305–353. doi: https://doi.org/10.1007/s00535-018-1439-1; Lee JW, Eun CS. Inflammatory bowel disease in Korea: epidemiology and pathophysiology. Korean J Intern Med. 2022;37(5):885–894. doi: https://doi.org/10.3904/kjim.2022.138; Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35(3):380–389. doi: https://doi.org/10.1111/jgh.14872; Agrawal M, Jess T. Implications of the changing epidemiology of inflammatory bowel disease in a changing world. United European Gastroenterol J. 2022;10(10):1113–1120. doi: https://doi.org/10.1002/ueg2.12317; Zippi M, Corrado C, Pica R, et al. Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients. World J Gastroenterol. 2014;20(46):17463–17467. doi: https://doi.org/10.3748/wjg.v20.i46.17463; Oviedo C, Yañez M, Pennacchiotti V. Frequency of oral manifestation in patients with inflammatory bowel disease in Chile. Int J Odontostomat. 2017;11(3):267–271. doi: https://doi.org/10.4067/S0718-381X2017000300267; Mohan Kumar KP, Nachiammai N, Madhushankari GS. Association of oral manifestations in ulcerative colitis: A pilot study. J Oral Maxillofac Pathol. 2018;22(2):199–203. doi: https://doi.org/10.4103/jomfp.JOMFP_223_16; Greuter T, Bertoldo F, Rechner R, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease: Prevalence, presentation and anti-TNF treatment. J Pediatric Gastroenterol. 2017;65(2):200–206. doi: https://doi.org/10.1097/MPG.0000000000001455; Kumar KM, Nachiammai N, Madhushankari GS. Association of oral manifestations in ulcerative colitis: A pilot study. J Oral Maxillofac Pathol. 2018;22(2):199–203. doi: https://doi.org/10.4103/jomfp.JOMFP_223_16; Salgado-Peralvo AO, Montero-Alonso M, Kewalramani N, et al. Prevalence of aphthous stomatitis in patients with inflammatory bowel disease after the treatment with monoclonal antibodies: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2022;27(6):e588–e599. doi: https://doi.org/10.4317/medoral.25528; Sbeit W, Kadah A, Mahamid M, et al. Oral manifestations of inflammatory bowel disease: the neglected piece of the puzzle. Eur J Gastroenterol Hepatol. 2020;32(11):1422–1431. doi: https://doi.org/10.1097/MEG.0000000000001918; Shazib MA, Byrd KM, Gulati AS. Diagnosis and Management of Oral Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2022;74(1):7–12. doi: https://doi.org/10.1097/MPG.0000000000003302; Zheng D, Xu Q, Liu Y. Atopic disease and inflammatory bowel disease: A bidirectional Mendelian randomization study. Medicine (Baltimore). 2024;103(42):e40143. doi: https://doi.org/10.1097/MD.0000000000040143; Li J, Wang L, Ma Y, Liu Y. Inflammatory bowel disease and allergic diseases: A Mendelian randomization study. Pediatr Allergy Immunol. 2024;35(5):e14147. doi: https://doi.org/10.1111/pai.14147; Zhang J, Xie H, Huang Y. Metabolic mediators of the causal relationship between inflammatory bowel disease and allergic rhinitis: insights from Mendelian randomization. J Clin Biochem Nutr. 2025;76(2):187–194. doi: https://doi.org/10.3164/jcbn.24; Docktor MJ, Paster BJ, Abramowicz S, et al. Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(5):935–942. doi: https://doi.org/10.1002/ibd.21874; Cappello F, Rappa F, Canepa F, et al. Probiotics Can Cure Oral Aphthous-Like Ulcers in Inflammatory Bowel Disease Patients: A Review of the Literature and a Working Hypothesis. Int J Mol Sci. 2019;20(20):5026. doi: https://doi.org/10.3390/ijms20205026; Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1–10. doi: https://doi.org/10.1007/s12328-017-0813-5; Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi: https://doi.org/10.1016/S0140-6736(16)32126-2; Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345–351. doi: https://doi.org/10.1016/j.cgh.2006.12.028; Latella G, Sferra R, Speca S, et al. Can we prevent, reduce or reverse intestinal fibrosis in IBD? Eur Rev Med Pharmacol Sci. 2013;17(10):1283–1304.; Gasparetto M, Angriman I, Guariso G. The multidisciplinary health care team in the management of stenosis in Crohn’s disease. J Multidiscip Healthc. 2015;8:167–179. doi: https://doi.org/10.2147/JMDH.S38729; Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719. doi: https://doi.org/10.3390/ijms22052719; Atreya R, Neurath MF. IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality. J Crohns Colitis. 2022;16(Suppl 2):ii54– ii63. doi: https://doi.org/10.1093/ecco-jcc/jjac007; Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. doi: https://doi.org/10.1016/j.jaad.2019.08.049; Tkach VY, Voloshynovych MS, Girnyk GY, Kozak NV. Clinical features and the course of psoriasis in children. Dermatology Review. 2020;107(5):476–480. doi: https://doi.org/10.5114/dr.2020.101677; Tangtatco JAA, Lara-Corrales I. Update in the management of pediatric psoriasis. Curr Opin Pediatr. 2017;29(4):434–442. doi: https://doi.org/10.1097/MOP.0000000000000517; Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6(5):813–820. doi: https://doi.org/10.1093/hmg/6.5.813; Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLAC and ERAP1. Nat Genet. 2010;42(11):985–990. doi: https://doi.org/10.1038/ng.69; Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8. doi: https://doi.org/10.1016/j.coi.2017.07.007; Kamata M, Tada Y. Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis. Front Immunol. 2022;13:941071. doi: https://doi.org/10.3389/fimmu.2022.941071; Campanati A, Ganzetti G, Di Sario A, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol. 2013;48(7):839–846. doi: https://doi.org/10.1007/s00535-012-0678-9; Bronckers IMGJ, Paller AS, Van Geel MJ, et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs. 2015;17(5):373–384. doi: https://doi.org/10.1007/s40272-015-0137-1; Becker L, Tom WL, Eshagh K, et al. Excess adiposity preceding pediatric psoriasis. JAMA Dermatol. 2014;150(5):573–574. doi: https://doi.org/10.1001/jamadermatol.2014.324; Thomas J, Parimalam K. Treating pediatric plaque psoriasis: Challenges and solutions. Pediatric Health Med Ther. 2016;7:25– 28. doi: https://doi.org/10.2147/PHMT.S75834; van de Kerkhof PCM, Nestlé FO. Psoriasis. In: Dermatology. Bolognia JL, Schaffer JV, Cerroni L, eds. 4th edn. Philadelphia, PA: Elsevier; 2018. pp. 138–160.; Tollefson MM. Diagnosis and management of Psoriasis in children. Pediatr Clin North Am. 2014;61(2):261–277. doi: https://doi.org/10.1016/j.pcl.2013.11.003; Хайрутдинов В.Р. Генетический паспорт больного псориазом // Вестник дерматологии и венерологии. — 2011. — № 4. — С. 14–19.; Chang CH, Stein SL. Malassezia-associated skin diseases in the pediatric population. Pediatr Dermatol. 2024;41(5):769–779. doi: https://doi.org/10.1111/pde.15603; Liu X, Cai Q, Yang H, et al. Distribution of Malassezia species on the skin of patients with psoriasis. J Mycol Med. 2021;31(2):101111. doi: https://doi.org/10.1016/j.mycmed.2021.101111; Magen E, Delgado JS. Helicobacter pylori and skin autoimmune diseases. World J Gastroenterol. 2014;20(6):1510–1516. doi: https://doi.org/10.3748/wjg.v20.i6.1510; McCormack G, Moriarty D, O’Donoghue DP, et al. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflammation Research. 2001;50(10):491–495. doi: https://doi.org/10.1007/PL00000223; Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329–342. doi: https://doi.org/10.1038/nri3661; Tatsuki M, Hatori R, Nakazawa T, et al. Serological cytokine signature in paediatric patients with inflammatory bowel disease impacts diagnosis. Sci Rep. 2020;10(1):14638. https://doi.org/10.1038/s41598-020-71503-y; Leppkes M, Neurath MF. Cytokines in inflammatory bowel diseases — Update 2020. Pharmacol Res. 2020;158:104835. doi: https://doi.org/10.1016/j.phrs.2020.104835; Medina Carbonell FR, Choyudhry Chandan O. Body Mass Index at Presentation of Inflammatory Bowel Disease in Children. Pediatr Gastroenterol Hepatol Nutr. 2020;23(5):439–446. doi: https://doi.org/10.5223/pghn.2020.23.5.439; Yerushalmy-Feler A, Ben-Tov A, Weintraub Y, et al. High and low body mass index may predict severe disease course in children with inflammatory bowel disease. Scand J Gastroenterol. 2018;53(6):708– 713. doi: https://doi.org/10.1080/00365521.2018.1464595; Vernon-Roberts A, Day AS. Promoting early testing and appropriate referral to reduce diagnostic delay for children with suspected inflammatory bowel disease, a narrative review. Transl Pediatr. 2023;12(7):1416–1430. doi: https://doi.org/10.21037/tp-23-35; Serrano-Gómez G, Mayorga L, Oyarzun I, et al. Dysbiosis and relapse-related microbiome in inflammatory bowel disease: A shotgun metagenomic approach. Comput Struct Biotechnol J. 2021;19:6481– 6489. doi: https://doi.org/10.1016/j.csbj.2021.11.037; Le ST, Toussi A, Maverakis N, et al. The cutaneous and intestinal microbiome in psoriatic disease. Clin Immunol. 2020;218:108537. doi: https://doi.org/10.1016/j.clim.2020.108537; De Pessemier B, Grine L, Debaere M, et al. Gut-skin axis: current knowledge of the interrelationship between microbial dysbiosis and skin conditions. Microorganisms. 2021;9(2):353. doi: https://doi.org/10.3390/microorganisms9020353; Polak K, Bergler-Czop B, Szczepanek M, et al. Psoriasis and Gut Microbiome-Current State of Art. Int J Mol Sci. 2021;22(9):4529. doi: https://doi.org/10.3390/ijms22094529; Hidalgo-Cantabrana C, Gómez J, Delgado S, et al. Gut microbiota dysbiosis in a cohort of patients with psoriasis. Br J Dermatol. 2019;181(6):1287–1295. doi: https://doi.org/10.1111/bjd.17931; Groot J, Blegvad C, Nybo Andersen AM, et al. Tonsillitis and pediatric psoriasis: Cohort and cross-sectional analyses of offspring from the Danish National Birth Cohort. J Am Acad Dermatol. 2020;82(3):666–674. doi: https://doi.org/10.1016/j.jaad.2019.08.010; Untaaveesup S, Amnartpanich T, Leelakanok N, et al. The prevalence and risk of allergic rhinitis in psoriasis patients: a systematic review and meta-analysis. Sci Rep. 2025;15(1):9009. doi: https://doi.org/10.1038/s41598-025-86779-1; Joel MZ, Fan R, Damsky W, Cohen JM. Psoriasis associated with asthma and allergic rhinitis: a US-based cross-sectional study using the All of US Research Program. Arch Dermatol Res. 2023;315(6):1823–1826. doi: https://doi.org/10.1007/s00403-023-02539-z.; https://www.pedpharma.ru/jour/article/view/2696 |